Mira, an AI-powered at-home hormone monitoring device, collaborates with fertility clinics in the U.S., Canada, and Australia to make fertility care more accessible by reducing the number of patient visits and minimizing testing costs. By using Mira’s fertility tracker, patients can track their hormones from home with lab-grade accuracy and avoid unnecessary clinic visits, and invasive blood draws.
On average, 2 million infants born in the US each year are conceived through assisted reproductive technology. The demand for treatments such as in vitro fertilization (IVF) has doubled in the last decade. However, only one in twenty-five couples in the US have access to the fertility care they need. In addition, fertility treatments are extremely stressful for the patient, and prohibitively expensive, with the cost of a single IVF cycle ranging from $15,000 to $30,000.
Therefore, most of the leading fertility clinics have set out to simplify treatment for the patient by making them more affordable and getting involved earlier in the patient’s journeys.
Mira’s partnership with fertility clinics helps fertility physicians escalate the number of treatments and reduce the cost of testing while improving patient experience. Incorporating Mira to the IVF protocol allows clinics to reduce the number of blood tests and in-person appointments by up to 3 times. It also equips fertility specialists with real-time, round-the-clock access to the patient’s hormone data and allows them to make informed decisions.
Mira has recently completed a trial with IVF patients in collaboration with Olive Fertility Center. The findings were presented at the American Society for Reproductive Medicine conference. The trial showed that urinary estrogen dynamics measured with Mira were comparable to those measured with serum estrogen. This means using Mira for at-home urine monitoring can be a valuable alternative to blood tests for patients undergoing IVF. It’s a huge step forward in making hormone tracking during fertility treatments more patient-friendly, convenient, and less intrusive.
Mira and Olive Fertility Center also plan on collaborating on a multicenter pilot to incorporate Mira in the natural-cycle frozen embryo transfer protocol. The Olive Fertility Center has recently started recommending Mira to their patients going through IUI.
“From my perspective as a reproductive endocrinologist and fertility specialist, Mira is a game-changing tool for patients and clinicians. With the convenience of home urine testing, the quantitative data of a laboratory blood test, and an informative and engaging app for hormone tracking—it seems to be the best of all worlds to improve the patient experience and optimize treatment outcomes. We are actively pursuing approaches to incorporate Mira into fertility treatments to reduce the burden of unnecessary blood tests and clinic visits.” – Dr. Gary Nakhuda, Reproductive Endocrinologist, co-founder, and medical director at Olive Fertility Center.
Mira is also working with Sama Fertility to help implement a more home-centric approach to fertility treatments. Experts at Sama have evaluated multiple solutions to replace blood tests while adding value to the patient and complementing their remote ovulation induction, IVF, and egg-freezing treatments. Trials show that Mira’s lab-grade accuracy is sufficient for making data-driven decisions about fertility treatments.
Genea is incorporating Mira in its clinical workflow to engage patients early in their journey. Proactive monitoring of patients’ hormone patterns allows their clinical team to make data-driven decisions about the patient’s treatment plan. Additionally, Genea is planning a clinical trial to include Mira in the treatment protocols replacing blood draws or reducing them to a minimal number. The initiative will make the treatments simpler and less stressful for Genea’s patients.
With Mira’s technology being the only one on the market meeting the strict requirements of IVF treatment, Mira aims to create a new standard of daily, at-home hormone monitoring across the whole spectrum of fertility treatments.
